Outlook
Outlook 2024/25
Elekta’s strategy provides the framework for our pursuit of profitable growth in a sustainable way and is quantified in the financial outlook.
Net sales and EBIT margin
In the full year of 2024/25, Elekta expect net sales to be broadly stable and the EBIT margin to be lower, compared to full year 2023/24.
Beyond this fiscal year, Elekta are targeting an EBIT margin of 14 percent or higher.
Dividend policy
Elekta’s goal is to provide shareholders with a favorable return and value growth. The policy is to distribute at least 50 percent of profit for the year in the form of dividend, repurchase of shares or comparable measures. A dividend decision is based on Elekta’s financial position, earnings trend, growth potential and investment requirements.
Dividend 2023/24
For 2023/24 the dividend amounted to 2.40 SEK/share, which corresponds to 70% of the net income.
Strategic milestones
Availability of care
In the second quarter of 2024/25, Elekta achieved our target of providing access to treatment via Elekta’s installed base of linacs (baseline 2019/20) to 300 million people in underserved markets.
Elevation of care
Online adaptive treatments are driven by Elekta Unity as the MR-Linac can adapt the treatment plan in real time to changing tumor and surrounding tissue anatomy.
During 2023/24, 100 percent of Unity treatments are adapted, of which around 60 percent are adapt to shape and around 40 percent adapt to position. More than 50 percent of Unity treatments are stereotactic body radiotherapy (hypofractionation).
Participation of care
Through the Kaiku app, patients can interact with their clinicians, who get access to the patients and their symptom feedback and will react to the patients
well-being, if necessary. A positive experience for the patient and efficient problem solving for the clinicians.
